Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Leap Therapeutics, Inc. (NASDAQ: LPTX).

Full DD Report for LPTX

You must become a subscriber to view this report.


Recent News from (NASDAQ: LPTX)

Leap Therapeutics to Participate in the H.C. Wainwright 20th Annual Global Investment Conference
CAMBRIDGE, Mass. , Aug. 30, 2018 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli , Ph.D., Chairman, President and Chief Executive Officer, will present...
Source: PR Newswire
Date: August, 30 2018 16:05
Recent Analysis Shows Leap Therapeutics, Gardner Denver, Medical Transcription Billing, CarGurus, Liberty Media, and Quorum Health Market Influences - Renewed Outlook, Key Drivers of Growth
NEW YORK, Aug. 22, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Leap Therapeutics, Inc. (NASDAQ:LPTX), Gardner Denver Holdings, Inc. (NYS...
Source: GlobeNewswire
Date: August, 22 2018 07:40
Leap Therapeutics Reports Second Quarter 2018 Business Update and Financial Results
CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported a business update and financial results for the second quarter ended June 30, 2018. “Over the pas...
Source: GlobeNewswire
Date: August, 08 2018 07:00
3 Things In Biotech, July 26: Takeda Looks For Its Piece Of The ALK Pie To Vindicate Ariad Acquisition
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Takeda marks a big win in first-line lung cancer Company: Takeda ( OTCPK:TKPYY ) T...
Source: SeekingAlpha
Date: July, 26 2018 08:00
Leap Therapeutics teams up with Merck KGaA and Pfizer to evaluate combo cancer treatment; shares up 6% premarket
Thinly traded micro cap Leap Therapeutics (NASDAQ: LPTX ) is up  6%  premarket on light volume in response to its announced collaboration with Merck KGaA ( OTCPK:MKGAY ) and Pfizer (NYSE: PFE ) to evaluate the combination of TRX518, Bavencio (avelumab) and chemo in patients with ...
Source: SeekingAlpha
Date: July, 23 2018 08:41
Leap Therapeutics Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Combination of TRX518, Avelumab, and Chemotherapy in Advanced Solid Tumors
CAMBRIDGE, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced it has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate ...
Source: GlobeNewswire
Date: July, 23 2018 07:30
Analysis: Positioning to Benefit within Ruth's Hospitality Group, S&P Global, Shaw Communications, Leap Therapeutics, Red Hat, and Welltower - Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, June 13, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ruth's Hospitality Group, Inc. (NASDAQ:RUTH), S&P Global Inc. (NYSE:S...
Source: GlobeNewswire
Date: June, 13 2018 07:55
Leap Therapeutics to Present at the 2018 JMP Securities Life Sciences Conference
CAMBRIDGE, Mass., June 13, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D., Chairman, President and Chief Executive Officer, will present a corp...
Source: GlobeNewswire
Date: June, 13 2018 07:00
Leap Therapeutics (LPTX) DKN-01 Program Update - Slideshow
The following slide deck was published by Leap Therapeutics in conjunction with this Read more ...
Source: SeekingAlpha
Date: May, 21 2018 13:37
Leap Therapeutics Reports First Quarter 2018 Financial Results
CAMBRIDGE, Mass., May 11, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2018. “We had a strong first quarter, as w...
Source: GlobeNewswire
Date: May, 11 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-087.417.097.417.0070,104
2018-05-178.087.788.487.6829119,875

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-0710,84615,89868.2224Short
2018-12-0615,22619,84676.7207Short
2018-12-047,69713,10458.7378Short
2018-12-038,92721,92740.7124Short
2018-11-305,03311,82342.5696Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on LPTX.


About Leap Therapeutics, Inc. (NASDAQ: LPTX)

Logo for Leap Therapeutics, Inc. (NASDAQ: LPTX)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $126,568,557 - 05/11/2018
  • Issue and Outstanding: 17,057,757 - 12/31/2015

 


Recent Filings from (NASDAQ: LPTX)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 23 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: March, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 22 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: March, 22 2018

 

 


Daily Technical Chart for (NASDAQ: LPTX)

Daily Technical Chart for (NASDAQ: LPTX)


Stay tuned for daily updates and more on (NASDAQ: LPTX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: LPTX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in LPTX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of LPTX and does not buy, sell, or trade any shares of LPTX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/